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Abstract
Background: Health facility characteristics associated with effective prevention of mother-to-child transmission of HIV
(PMTCT) coverage in sub-Saharan are poorly understood.
Methodology/Principal Findings: We conducted surveys in health facilities with active PMTCT services in Cameroon, Cote
d’Ivoire, South Africa, and Zambia. Data was compiled via direct observation and exit interviews. We constructed composite
scores to describe provision of PMTCT services across seven topical areas: antenatal quality, PMTCT quality, supplies available,
patient satisfaction, patient understanding of medication, and infrastructure quality. Pearson correlations and Generalized
Estimating Equations (GEE) to account for clustering of facilities within countries were used to evaluate the relationship
between the composite scores, total time of visit and select individual variables with PMTCT coverage among women
delivering. Between July 2008 and May 2009, we collected data from 32 facilities; 78% were managed by the government
health system. An opt-out approach for HIV testing was used in 100% of facilities in Zambia, 63% in Cameroon, and none in
Coˆte d’Ivoire or South Africa. Using Pearson correlations, PMTCT coverage (median of 55%, (IQR: 33–68) was correlated with
PMTCT quality score (rho= 0.51; p = 0.003); infrastructure quality score (rho= 0.43; p = 0.017); time spent at clinic (rho= 0.47;
p = 0.013); patient understanding of medications score (rho= 0.51; p = 0.006); and patient satisfaction quality score (rho= 0.38;
p = 0.031). PMTCT coverage was marginally correlated with the antenatal quality score (rho= 0.304; p = 0.091). Using GEE
adjustment for clustering, the, antenatal quality score became more strongly associated with PMTCT coverage (p,0.001) and
the PMTCT quality score and patient understanding of medications remained marginally significant.
Conclusions/Results: We observed a positive relationship between an antenatal quality score and PMTCT coverage but did
not identify a consistent set of variables that predicted PMTCT coverage.
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Introduction
Despite the universal recognition of efficacious interventions
and unprecedented resources to reduce MTCT (mother to child
transmission), in 2009, only 26% of pregnant women living in low
and middle income countries had been tested for HIV and among
identified HIV-positive women, only an estimated 53% received
an antiretroviral (ARV) regimen to prevent mother-to-child HIV
transmission (PMTCT) [1]. As a result of the failure of health
systems to effectively deliver PMTCT regimens, approximately
1,000 children under the age of 15 continue to be infected with
HIV every day, the vast majority around the time of birth and
through breastfeeding [1].
While multiple studies have measured PMTCT efficacy, studies
that describe determinants of PMTCT program effectiveness are
rare. The few published reports that have assessed PMTCT
program effectiveness have not addressed reasons for successes and
failures [2–4]. A multi-site PMTCT effectiveness study in four
African countries called PMTCT Effectiveness in Africa: Research
and Linkages to Care (the PEARL Study) was conducted between
2007–2009, and found that coverage of nevirapine (NVP) among
HIV-infected women delivering in health facilities with PMTCT
services varied dramatically and was only 55% overall [5].
A better understanding of barriers to high PMTCT coverage is
needed with the new 2010 World Health Organization (WHO)
guidelines promoting more efficacious ARV combination regi-
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mens for women and extended infant prophylaxis during
breastfeeding. Implementation of the new guidelines will require
higher quality antenatal - and PMTCT care, more rigorous infant
follow up, and ongoing maternal care after delivery [6]. More
complex PMTCT regimens will also require a greater under-
standing of what occurs at the health facility level and where
investments need to be made [1,7,8]. Using data from the PEARL
Study, we examine how facility and service characteristics predict
maternal-infant coverage with NVP at the time of delivery.
Methods
The PEARL study was a multi-country evaluation of PMTCT
effectiveness at the patient, facility, and community levels. We
previously reported PMTCT coverage in a survey among women
delivering in 43 health facilities in Cameroon, Cote d’Ivoire, South
Africa, and Zambia between 2007 and 2009 [5]. PMTCT
coverage was defined as the proportion of HIV-positive mother-
HIV-exposed baby pairs in which both received single-dose NVP.
Maternal dosing was confirmed by biochemical measurement in
the cord blood and newborn dosing was confirmed by chart review
[5]. As part of this study, we completed facility surveys at delivery
centers which also provided antenatal care.
Data collection
We used a modified version of ‘‘A Rapid Health Facility
Assessment Tool: to Enhance Quality and Access at the Primary
Health Care Level.’’ This tool was developed in 2006 by ICF
Macro in collaboration with MEASURE Evaluation and a panel
of experts from the United States Agency for International
Development (USAID) and other cooperating agencies and
modified to include detailed PMTCT information in parallel with
other antenatal care information. The original tool is available
online http://www.mchipngo.net/controllers/link.cfc?method =
tools_rhfa.
The questionnaire included general questions such as type of
facility, estimated size of the catchment area, and location as well
as four discrete modules on clinic operations. Each module
contained 32–120 questions. Modules included direct observation
of clinician patient encounters, exit interviews of patients, and
questions of patients and providers.
N Module 1 was a quality-of-care checklist completed by direct
observation of an antenatal consultation. Up to six consecutive
antenatal visits in each facility were observed. Only first ANC
visit observations were used.
N Module 2 was an exit interview with up to six consecutive
pregnant women after the consultation to measure patient
perceptions about care. Key measurements were satisfaction
and understanding of each medicine or prescription given
during the consultation.
N Module 3 was a checklist of available infrastructure, equip-
ment and supplies (including drugs).
N Module 4 was an interview with the health center manager
regarding services provided, numbers of personnel, and other
staffing variables.
The survey instrument was adapted and translated into French
in Coˆte d’Ivoire and was pretested in the four countries prior to
data collection. All questionnaires were entered into a Microsoft
Access database and sent to PEARL’s central data management
and analysis unit.
We examined each variable (n = 377) in the questionnaire
individually to determine which ones were associated with
PMTCT coverage. In addition, we created seven composite
scores that summarized features of the clinic in several domains in
a systematic manner. These scores were developed a priori by the
study co-investigators based on logical groupings of characteristics,
and included composite scores for antenatal care, PMTCT,
supplies, staffing level, patient satisfaction, general infrastructure,
and patient understanding of medications. Scores were adjusted by
country to account for different standards of care (e.g. items
relating to malaria were not considered for South Africa since
South Africa does not include malaria prophylaxis in routine
antenatal care). Table S1 summarize the variables used and how
the scores were constructed.
In addition, time-motion variables were constructed from the
average of up to six patient observations at each facility. Time was
recorded at a) registration b) start of exam and c) visit finish
(including receipt of medication at pharmacy), allowing the
calculation for the median total time of the visit as well as the
time spent post test counseling.
Antenatal and PMTCT domains were assigned a score of (1) if
appropriate care or treatment was given; (0.5) if appropriate care
or treatment was given but not recorded in the chart; and (0) if
appropriate care was not given. This was done because failure to
record information, such as an HIV test, CD4 count, or blood
pressure reading will lead to failure to act upon this critical
information throughout the pregnancy. Infrastructure, supplies,
and staff domains were assigned a score of (1) when available and
(0) when not available. Scores were totaled for each domain, and
divided by the number of items included. Non-applicable
information and missing items were not considered in the scoring.
Final domain scores were thus a proportion between 0 and 1, with
a higher score reflecting more appropriate care. Patient satisfac-
tion was scored on a scale of 1 to 5, with 5 being extremely
satisfied and 1 being extremely unsatisfied. For patient compre-
hension, (1) point was given for each correct response for each
criteria (dose, frequency, duration, and purpose), and (0) points
were given for incorrect responses. (Table 1 summarizes the
construction of health facility quality scores.
Statistical analysis
All PEARL study facilities with cord blood and facility survey
data were included. Site characteristics were summarized using
descriptive statistics. We computed means and standard deviations
or medians and inter-quartile ranges for continuous variables and
percentages for categorical variables. Using all facilities from all 4
countries and PMTCT coverage as a continuous outcome
measure, separate regression models were fit for health facility
characteristics of interest and the quality scores. Generalized
estimating equations (GEE) with an exchangeable correlation
structure were used to account for country program -related
correlation between facilities in the same country.
Statistical analyses were performed using SASH version 9.1.3
(SAS Institute, Cary, NC, USA) and StataH version 10.0
(StataCorp. 2007. Stata Statistical Software: Release 10. College
Station, TX).
Ethical review and role of the funding source
Approval was provided by institutional or national review
boards at the U.S. Centers for Disease Control and Prevention
(CDC), the University of Alabama at Birmingham, and each of the
participating countries a) Comite d’e´thique des sciences et de la
vie, Ministe`re de la Sante´, Coˆte d’Ivoire, b) University of Zambia
Research Ethics Committee, Lusaka Zambia, c) Cameroon Baptist
Convention Health Board, Bamenda, Northwest Province,
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Cameroon, d) South African Medical Research Council Ethics
Committee, Cape Town, South Africa.
Verbal consent was obtained among the health care workers
and the selected pregnant women who participated in the direct
interview during this survey. The corresponding author had access
to all data in the study and final responsibility for the decision to
submit this manuscript.
Results
Description of the health facilities
Cord blood and facility survey data were collected from 32
facilities (8 facilities in Cameroon, 9 facilities in Cote d’Ivoire, 6 in
South Africa, and 9 in Zambia). Most were health centers
managed by their respective governments. General characteristics
of facilities and their services are described in Table 1, An opt-out
approach for HIV testing was used in 100% of facilities in Zambia,
63% in Cameroon, and none in Coˆte d’Ivoire and South Africa
(Table 1) Antenatal care service provision among observed
patients by country is described in Table 2.
Relationship of individual facility and service
characteristics to NVP coverage
Table S2 shows the relationships between facility characteristics,
observed service provision, and NVP coverage. Higher coverage
was associated with HIV test kits being found in ANC (as opposed
to in the lab), HIV testing available in labor ward, availability of
CD4 testing at the clinic, infant testing with PCR available most
days of the month, and the presence of an antenatal register with
PMTCT information. PMTCT coverage was not associated with
type of facility, location of HIV testing during antenatal care,
reported opt-in or opt-out testing strategy, same day HIV results,
partner HIV testing, time of dispensation of NVP (at first antenatal
visit, later in pregnancy or upon arrival at the facility in labor), or
the presence of lay counselors.
Relationship of a priori composite quality scores to NVP
coverage
Table 3 shows the seven composite quality scores and two time
variables stratified by country, and their relationship with NVP
Table 1. Health facility characteristics by country; PEARL Facility Survey, 2007–2009.
Cameroon
(n =8)
Cote d’Ivoire
(n=9)
South Africa*
(n =6)
Zambia
(n =9)
Overall
(N=32)
Type of facility (%)
Hospital 63% 22% 0% 33% 31%
Health Center 38% 78% 100% 67% 69%
Managing authority (%)
Government/Public 50% 89% 100% 78% 78%
NGO, Faith-based, Private 50% 11% 0% 22% 22%
Urban/Rural (%)
Rural 63% 33% 67% 56% 53%
Urban 38% 67% 33% 44% 47%
Education talk£ (%)
No 0% 11% 0% 0% 3%
Yes 100% 89% 100% 100% 97%
Total catchment population
– median (IQR): inhabitants
38,177 (19,622–42,135) 96,597 (58,216–169,320) 26,229 (12,000–37,729) 20,841 (17,113–29,871) 38,089(20,232–70,910)
Under five children in
catchment area - median (IQR)
4,556 (1,527–7,585) 10,124 (4,845–19,536) 500 (481–3,118) 2,408 (1,678–6,278) 3,118 (1,326–9,126)
HIV pre-test counseling (%)
Group 38% 33% 0% 100% 47%
Individual 38% 67% 100% 0% 47%
Not Done 25% 0% 0% 0% 6%
HIV testing (%)
Opt In 38% 100% 100% 0% 56%
Opt-Out 63% 0% 0% 100% 44%
CD4 testing available (%)
All or most days 25% 33% 100% 44% 47%
No 75% 67% 0% 56% 53%
ART available for pregnant
women (%)
Provided at this clinic 38% 89% 33% 78% 63%
Transfer to other clinics 63% 11% 67% 22% 38%
£: Note that this item is not related to HIV, but to maternal and infant health in general.
*Survey was conducted in delivery facilities where antenatal activities are implemented.
IQR: Interquartile range.
doi:10.1371/journal.pone.0029823.t001
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coverage. In univariate analysis using Pearson correlation (not
adjusted for the clustering of facilities within countries), PMTCT
coverage was correlated with higher PMTCT quality score
(p = 0.003); infrastructure quality score (p = 0.017); patient satis-
faction quality score (p = 0.031); and patient understanding of
medications score (p = 0.006), and was marginally correlated with
the antenatal quality score (p = 0.091). There was no correlation
between PMTCT coverage and staff quality score (p = 0.168) or
supply quality score (p = 0.812). PMTCT coverage was associated
with longer total time at the clinic (p = 0.013), but not longer time
spent for post-test counseling (p = 0.938).
When we accounted for clustering using GEE, only antenatal
quality score (p,0.001) remained significantly positively correlated
with PMTCT coverage (Figure 1), but PMTCT quality score and
patient satisfaction score remained marginally significant (Figure 2).
Discussion
This facility survey was conducted in sites at which we already
knew the PMTCT coverage level from the previously-published
cord blood study [5]. The exercise thus presented a unique
opportunity to both describe facility factors associated with
Table 2. Antenatal care service provision among observed patients, by country; PEARL Facility Survey, 2007–2009{.
Cameroon
(n =8)
Cote d’Ivoire
(n=9)
South Africa
(n =6)
Zambia
(n =9)
Overall
(N=32)
Patient weighed - mean (std) 100 (0) 100 (0) 100 (0) 100 (0) 100 (0)
Blood pressure taken - mean (std) 90 (19) 80 (40) 100 (0) 98 (6) 92 (24)
Fundal height palpated - mean (std) 98 (6) 89 (33) 100 (0) 98 (6) 96 (18)
Fetal heart tones checked- mean (std) 83 (37) 56 (43) 100 (0) 98 (6) 83 (33)
Urine dipped for protein – mean (std) 57 (53) 73 (41) 100 (0) 0 (0) 53 (49)
Blood drawn for syphilis test - mean (std) 54 (13) 18 (27) 100 (0) 87 (33) 62 (40)
Blood drawn for hemoglobin test - mean (std) 64 (24) 12 (24) 100 (0) 78 (37) 60 (42)
Blood drawn for HIV test – mean (std) 71 (27) 70 (38) 97 (7) 100 (0) 84 (27)
Number of CBS mother/baby pairs - median (IQR) 81
(67–122)
52
(34–84)
22
(21–115)
71
(54–142)
67
(33–120)
Full coverage** - median (IQR) 78 (59–84) 15 (9–18) 56 (48–59) 59 (54–62) 55 (33–68)
CBS: Cord blood specimens, IQR: Interquartile range, std: standard deviation.
**full coverage defined as the proportion of HIV-exposed infants in the sample with both maternal nevirapine ingestion (confirmed by cord blood chromatography) and
infant nevirapine ingestion (confirmed by direct observation).
{For the direct observation patient measures we first calculated the percent observed at each facility among the up to 6 cases and then computed the mean (and
standard deviation) of those facility-level percents to get the overall country values shown in the table.
doi:10.1371/journal.pone.0029823.t002
Table 3. Health facility quality scores and correlation with PMTCT coverage, PEARL Facility Survey, 2007–2009.
Cameroon Cote d’Ivoire South Africa Zambia Overall r p value
GEE
estimate
GEE
p-value*
ANC quality score
– median (IQR)
67 (58–76) 62 (61–69) 77 (60–81) 67 (64–73) 67 (61–74) 0.304 0.091 4.81 ,0.001
PMTCT quality score
- median (IQR)
72 (67–78) 64 (60–68) 86 (78–88) 74 (70–80) 74 (67–81) 0.509 0.003 5.89 0.071
Staff quality score
– median (IQR)
66 (62–73) 62 (56–75) 69 (60–76) 74 (72–82) 72 (60–78) 0.250 0.168 2.60 0.243
Supplies quality score
- median (IQR)
76 (68–83) 73 (68–78) 51 (46–54) 68 (62–90) 70 (58–80) 20.043 0.812 20.62 0.340
Infrastructure quality
score - median (IQR)
87 (67–92) 69 (62–75) 79 (75–81) 65 (65–81) 75 (65–82) 0.425 0.017 2.44 0.088
Patient satisfaction quality
score - median (IQR)
4 (4-4) 4 (4-4) 4 (4–5) 4 (4-4) 4 (4-4) 0.383 0.031 5.78 0.060
Patient understanding
of medications score
- median (IQR)
83 (74–89) 50 (44–81) 86 (72–100) 99 (94–100) 86 (69–97) 0.507 0.006 0.02 0.986
Total time (minutes) 281(212–325) 154(113–239) 268(243–293) 327(230–379) 250 (160–327) 0.472 0.013 0.36 0.743
Post-test counseling
time (minutes)
4 (3–4) 5 (3–6) 4 (2–5) 13 (7–14) 5 (4–9) 0.016 0.938 0.22 0.145
r: Pearson correlation coefficient, IQR: Interquartile range.
*p-value for univariate regression models treating coverage as a continuous measure, using GEE to account for correlation due to clustering of facilities within countries.
doi:10.1371/journal.pone.0029823.t003
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PMTCT coverage and to begin to validate the survey tool as a
predictor of program performance. To our knowledge, this is the
first study to examine in a systematic way the relationship between
antenatal clinic and service characteristics and an objective
outcome such as PMTCT coverage.
Many variables were associated with higher coverage, both
individually and in two of the aggregate scores. Some, including
availability of CD4 testing and infant PCR testing were intuitively
satisfying and agree with our preconceived notions about how
programs evolve to be more sophisticated and more successful. We
did learn a few new things, however, including that variables
pertaining to general antenatal care were even more predictive
than PMTCT variables, and that the single factor distinguishing
all of the worst-performing sites from the others was the lack of
registers with PMTCT information. The predictive value of the
non-PMTCT variables, and the lack of predictiveness of several
Figure 1. Relationship between composite ANC score and PMTCT coverage. PEARL Facility Survey, 2007–2009.
doi:10.1371/journal.pone.0029823.g001
Figure 2. Relationship of composite PMTCT score and PMTCT coverage, PEARL Facility Survey, 2007–2009. Areas of the circles are
proportional to the size of the cord blood sample used to estimate PMTCT coverage Line is based on the GEE model that accounts for clustering.
doi:10.1371/journal.pone.0029823.g002
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PMTCT variables, reminds us that complex PMTCT services
cannot be expected to function well where overall services are
poor, even if all the elements of PMTCT are provided.
Overall, we concluded that this tool has limited but not zero
utility as a method of evaluating PMTCT sites. Certainly
programs do need to know if the essential elements of PMTCT
and antenatal care are in place, and common sense dictates that
PMTCT requires the presence of drugs, trained staff, and properly
stored test kits. However, presence of these elements does not
necessarily ensure successful implementation, and answers ob-
tained in this simple checklist-based survey and patient exit
interview do not necessarily reflect the experiences of patients
visiting the facilities. The overall low coverage of NVP in our study
sites (55%, range 33% to 68%) indicates that something is amiss in
these PMTCT sites. The aggregate PMTCT score did have some
relationship with coverage overall, but not in all countries, and the
PMTCT scores were relatively homogeneous compared to the
very large observed differences in coverage. Provision of
longitudinal medical care and the population’s receptiveness to
this medical care is a complex process dependent upon attitudes,
beliefs, trust, relationships, and complex elements of clinic flow
and individual interactions. Most of this cannot be adequately
described using simple inventories such as this one, even with
direct observation of some elements of care.
Several variables that we expected to be associated with higher
PMTCT coverage were not, and on close analysis of the questions
and data we appreciated weaknesses in the survey tool that are
important to help guide future program evaluation efforts. For
example, we asked clinic managers if their site conducted ‘‘opt-
out’’ HIV testing. Though several studies have shown that opt-out
testing increases uptake [9,10]. There was no association between
opt-out testing and higher PMTCT coverage in our study. Asking
clinic managers was probably not the right approach. In an
operational sense, opt-out testing is defined not by the policy in
place, but by the details of how testing is explained to clients and
how they, their laboratory forms, and their blood move through
the clinic during their visit. A checklist survey approach does not
lend itself to an adequate description of how this occurs, and it is
doubtful that we truly distinguished between opt-out and opt-in
approaches. There are other examples as well. We found that
availability of antiretroviral therapy (ART) at the clinic did not
predict PMTCT coverage. Simply having ART at the same site
does not tell us how well the ART and antenatal clinics work
together to ensure that all eligible women receive ART during
pregnancy. The details of how the services are integrated will
determine successful provision of ART in pregnancy. Meaningful
exploration of these issues requires a different type of evaluation.
Our study has several recognized limitations. Since we decided
to include only sites that provided both antenatal and delivery
services, we included a relatively small number of facilities across
four countries. The small sample size may have impacted the
statistical power to detect associations between our composite
scores as well as individual variables and PMTCT coverage.
Second, with only six consecutive observations per facility selected,
it is possible that the result for any one site might not be
representative of that site’s performance (sampling error). This
could lead to exposure misclassification and undermine the ability
to observe a true association.
Our results broadly support the general principle of strength-
ening the health care system as an important strategy for
improving PMTCT coverage. This analysis exercise provides an
important reminder for programs that service provision is
complex, and that provision of drugs, test kits, policies, and
training does not ensure program success. It is also an important
caution to program evaluators that even this carefully conceived
and detailed site survey could not predict which sites did well in a
very useful way. Once basic elements of PMTCT are in place,
detailed clinic-level quality improvement and problem solving
initiatives that focus on operational factors are probably just as
essential. Further study surrounding quality improvement methods
and their impact on coverage and outcomes is warranted.
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